Abzena is the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules with headquarters in San Diego, CA and additional centres of excellence in Bristol, PA and Cambridge, UK. Abzena has extensive experience in developing Biologics and Bioconjugates, and provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. Forward-thinking and committed, Abzena finds the best solutions and uses the right technologies to design, develop and manufacture products to ensure we get vital medicines to patients. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors and Biospring Partners.
Location: United Kingdom
Employees: 501-1000
Total raised: $75M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Beringea | beringea.c... |
| - | Beringea | beringea.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.03.2022 | Private Eq... | $65M | - |
| 28.07.2020 | - | $10M | - |
Mentions in press and media 23
| Date | Title | Description |
| 31.01.2025 | Savant Labs Secures $18.5M to Revolutionize Data Analytics | In the fast-paced world of data analytics, Savant Labs is making waves. The San Mateo-based company recently secured $18.5 million in Series A funding, led by Dell Technologies Capital. This investment is not just a financial boost; it’s a ... |
| 31.01.2025 | Savant Labs Raises $18.5M in Series A Funding | Savant Labs, a San Mateo, CA-based provider of an AI-powered platform helping business analysts access and manage data, raised $18.5M in Series A funding. The round was led by Dell Technologies Capital (DTC), with participation from Vertex ... |
| 07.01.2025 | Assessment of Fc-mediated Functional Activity for the Development of Complex Biologics and Bioconjugates, Upcoming Webinar Hosted by Xtalks | www.abzena.com In this free webinar, learn the best approaches to assess Fc function (antibody-dependent cellular cytotoxicity [ADCC], antibody-dependent cellular phagocytosis [ADCP] and complement-dependent cytotoxicity [CDC]) for drug dis... |
| 16.08.2024 | Mastering the Art of Developing a Successful Bispecific Antibody, Upcoming Webinar Hosted by Xtalks | www.abzena.com In this free webinar, learn what elements to include and avoid when optimizing bispecific candidate design. Attendees will discover how to enhance antibody purity with single-step purification. The featured speakers will disc... |
| 28.05.2024 | Accelerate Early-Phase Biologics from the Clinic to Commercialization: Key Technologies & Strategies in Cell-Based Manufacturing, Upcoming Webinar with Abzena & Sartorius | www.abzena.com In this free webinar, learn about key strategies that speed upaccelerate monoclonal antibody (mAbs) products and therapies from the clinic to commercial scale-up. These include employing fully integrated end-to-end single-use... |
| 26.04.2024 | Abzena launches EpiScreen® 2.0 Immunogenicity platform | Abzena launches EpiScreen® 2.0, a next generation immunogenicity tool for de-risking the development of complex biologics and bioconjugates. Cambridge, UK - Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjuga... |
| 28.03.2024 | Abzena announces major investment in Bioconjugation and ADC capabilities | Abzena announces major investment in Bioconjugation and ADC capabilities in response to increasing industry demand. Bristol, PA, March 27, 2024 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announ... |
| 12.03.2024 | Antibody-Drug Conjugates: Next-Generation Linker Technology for IND Submissions, Upcoming Webinar Hosted by Xtalks | www.abzena.com In this free webinar, gain insights into designing and developing a bioconjugate or antibody-drug conjugates (ADC). Attendees will learn about the impactful role of linker technologies in accelerating and de-risking the devel... |
| 17.01.2024 | Abzena launches AbZelect CLD platforms | Abzena launches AbZelect™ platforms for improving cell line development efficiency on the pathway to IND. San Diego, CA - Abzena, the leading end-to-end CDMO for biologics and bioconjugates, has launched AbZelect™ and AbZelectPRO™ cell line... |
| 12.04.2022 | Abzena commits chunk of new $65M investment to build out in hot North Carolina scene | A San Diego CDMO has landed a $65 million investment to expand its drug substance and fill-finish manufacturing capacity, and it’s putting some of the money into its newest site on the other side of the country. Abzena wi... |
Show more